AI주식인사이트AI Stock Insight
C

대화제약

067080KOSDAQ의약품 제조업

42.8 / 100

Reference Date: 2026-06-10

Financial Score9.5 / 40
News Sentiment21.3 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Plunged 23.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Hwa Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, medical devices, and raw materials, supplying a wide range of products such as antibiotics and pain relievers both domestically and internationally. The company has expanded its overseas markets through partnerships with German and Chinese firms and focuses on R&D investment for new drug development.

Number of Employees

369people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
114.89Industry Average 11.930.0Point

9.6x industry avg (risky)

PBR
2.54Industry Average 0.890.0Point

2.9x industry avg (risky)

ROE
3.00Industry Average 4.012.5Point

Below industry avg

Debt Ratio
12.94Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲94.5% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 1.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 10,800Won52-week high 23,30052-week low 10,800
1-month return0.0Point

1m -23.67% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
  • Neutral분기보고서 (2026.03)2026-05-15
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-14
  • Neutral투자판단관련주요경영사항 (리포락셀액(파클리탁셀)의 품목허가사항 변경허가 승인(유방암 신규 적응증 추가 허가 승인))2026-05-13